{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:41:10Z","timestamp":1767984070212,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05605-5","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T17:40:07Z","timestamp":1744998007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group)"],"prefix":"10.1007","volume":"43","author":[{"given":"Ahmed","family":"Eraky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Bignante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres F.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Eun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ditonno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Abdollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandru P.","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol C.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Rais-Bahrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark L.","family":"Gonzalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omri Falik","family":"Nativ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Amparore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Checcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisto","family":"Perdon\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Br\u00f6nimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Tuderti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F.","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ithaar H.","family":"Derweesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Bhanvadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H.","family":"Zahalka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad S.","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Djaladat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8648-0410","authenticated-orcid":false,"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"5605_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, Seisen T, Birtle AJ, Capoun O, Comp\u00e9rat EM, Dominguez-Escrig JL et al (2023) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 Update. Eur Urol 84:49\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013","journal-title":"Eur Urol"},{"key":"5605_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","volume":"209","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R et al (2023) Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO Guideline. J Urol 209:1071\u20131081. https:\/\/doi.org\/10.1097\/JU.0000000000003480","journal-title":"J Urol"},{"key":"5605_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1200\/JCO.23.02679","volume":"42","author":"SA Berg","year":"2024","unstructured":"Berg SA, Galsky MD (2024) Understanding adjuvant therapy for upper tract urothelial carcinoma. JCO 42:1459\u20131461. https:\/\/doi.org\/10.1200\/JCO.23.02679","journal-title":"JCO"},{"key":"5605_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J (2021) Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol 79:635\u2013654. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","journal-title":"Eur Urol"},{"key":"5605_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"JA Witjes","year":"2024","unstructured":"Witjes JA, Bruins HM, Carri\u00f3n A, Cathomas R, Comp\u00e9rat EM, Efstathiou JA, et al. (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 85:17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016","journal-title":"Eur Urol"},{"key":"5605_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA et al (2016) Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21:708\u2013715. https:\/\/doi.org\/10.1634\/theoncologist.2015-0440","journal-title":"Oncologist"},{"key":"5605_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.23.01659","volume":"42","author":"AJ Birtle","year":"2024","unstructured":"Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M et al (2024) Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial. JCO 42:1466\u20131471. https:\/\/doi.org\/10.1200\/JCO.23.01659","journal-title":"JCO"},{"key":"5605_CR8","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"5605_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R et al (2025) Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med 392:45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726","journal-title":"N Engl J Med"},{"key":"5605_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D et al (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:525\u2013537. https:\/\/doi.org\/10.1016\/S1470-2045(21)00004-8","journal-title":"Lancet Oncol"},{"key":"5605_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaoncol.2017.2374","volume":"4","author":"T Seisen","year":"2018","unstructured":"Seisen T, Jamzadeh A, Leow JJ, Roupr\u00eat M, Cole AP, Lipsitz SR et al (2018) Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. JAMA Oncol 4:225\u2013229. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2374","journal-title":"JAMA Oncol"},{"key":"5605_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jjco\/hyab210","volume":"52","author":"M Omura","year":"2022","unstructured":"Omura M, Kikuchi E, Shigeta K, Ogihara K, Hakozaki K, Hara S et al (2022) Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer. Jpn J Clin Oncol 52:388\u2013396. https:\/\/doi.org\/10.1093\/jjco\/hyab210","journal-title":"Jpn J Clin Oncol"},{"key":"5605_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3233\/BLC-170107","volume":"3","author":"W Sui","year":"2017","unstructured":"Sui W, Lim EA, Joel Decastro G, McKiernan JM, Anderson CB (2017) Use of adjuvant chemotherapy in patients with advanced bladder cancer after neoadjuvant chemotherapy. Bladder Cancer 3:181\u2013189. https:\/\/doi.org\/10.3233\/BLC-170107","journal-title":"Bladder Cancer"},{"key":"5605_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clgc.2017.07.010","volume":"16","author":"WP Parker","year":"2018","unstructured":"Parker WP, Habermann EB, Day CN, Zaid HB, Frank I, Thompson RH et al (2018) Adverse pathology after neoadjuvant chemotherapy and radical cystectomy: the role of adjuvant chemotherapy. Clin Genitourin Cancer 16:64-71.e5. https:\/\/doi.org\/10.1016\/j.clgc.2017.07.010","journal-title":"Clin Genitourin Cancer"},{"key":"5605_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA et al (2022) NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 20:866\u201378. https:\/\/doi.org\/10.6004\/jnccn.2022.0041","journal-title":"J Natl Compr Canc Netw"},{"key":"5605_CR16","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1200\/JCO.22.00763","volume":"41","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G et al (2023) Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma. J Clin Oncol 41:1618\u20131625. https:\/\/doi.org\/10.1200\/JCO.22.00763","journal-title":"J Clin Oncol"},{"key":"5605_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5489\/cuaj.8570","volume":"17","author":"MD Ho","year":"2023","unstructured":"Ho MD, Black AJ, Zargar H, Fairey AS, Mertens LS, Dinney CP et al (2023) The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy. Can Urol Assoc J 17:301\u2013309. https:\/\/doi.org\/10.5489\/cuaj.8570","journal-title":"Can Urol Assoc J"},{"key":"5605_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30:970\u2013976. https:\/\/doi.org\/10.1093\/annonc\/mdz127","journal-title":"Ann Oncol"},{"key":"5605_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4111\/kju.2015.56.1.41","volume":"56","author":"KS Lee","year":"2015","unstructured":"Lee KS, Kim KH, Yoon YE, Choi KH, Yang SC, Han WK (2015) Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy. Korean J Urol 56:41\u201347. https:\/\/doi.org\/10.4111\/kju.2015.56.1.41","journal-title":"Korean J Urol"},{"key":"5605_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2008.07.035","volume":"73","author":"W Kassouf","year":"2009","unstructured":"Kassouf W, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL et al (2009) OUTCOME OF BLADDER CANCER PATIENTS WITH pN+ DISEASE AFTER PREOPERATIVE CHEMOTHERAPY AND RADICAL CYSTECTOMY. Urology 73:147\u2013152. https:\/\/doi.org\/10.1016\/j.urology.2008.07.035","journal-title":"Urology"},{"key":"5605_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.euo.2018.12.013","volume":"3","author":"N Martinez Chanza","year":"2020","unstructured":"Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ et al (2020) Incidence, patterns, and outcomes with adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy in muscle-invasive urinary tract cancers. Eur Urol Oncol 3:671\u2013679. https:\/\/doi.org\/10.1016\/j.euo.2018.12.013","journal-title":"Eur Urol Oncol"},{"key":"5605_CR22","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.3390\/ijms23095154","volume":"23","author":"K Shigeta","year":"2022","unstructured":"Shigeta K, Matsumoto K, Tanaka N, Mikami S, Kosaka T, Yasumizu Y et al (2022) Profiling the biological characteristics and transitions through upper tract tumor origin, bladder recurrence, and muscle-invasive bladder progression in upper tract urothelial carcinoma. Int J Mol Sci 23:5154. https:\/\/doi.org\/10.3390\/ijms23095154","journal-title":"Int J Mol Sci"},{"key":"5605_CR23","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00345-016-1825-3","volume":"34","author":"K Zargar-Shoshtari","year":"2016","unstructured":"Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA et al (2016) Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol 34:1567\u20131573. https:\/\/doi.org\/10.1007\/s00345-016-1825-3","journal-title":"World J Urol"},{"key":"5605_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P, Godoy G, Chen M, Smaldone MC et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581\u2013587. https:\/\/doi.org\/10.1016\/j.eururo.2010.06.029","journal-title":"Eur Urol"},{"key":"5605_CR25","doi-asserted-by":"publisher","first-page":"852969","DOI":"10.3389\/fsurg.2022.852969","volume":"9","author":"A Peyrottes","year":"2022","unstructured":"Peyrottes A, Califano G, Ouza\u00efd I, Lain\u00e9-Caroff P, Long Depaquit T, Hermieu J-F et al (2022) Lymph node dissection during radical nephro-ureterectomy for upper tract urothelial carcinoma: a review. Front Surg 9:852969. https:\/\/doi.org\/10.3389\/fsurg.2022.852969","journal-title":"Front Surg"},{"key":"5605_CR26","unstructured":"Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature - ScienceDirect n.d. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0302283812002242. Accessed 17 Sept 2024"},{"key":"5605_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.889144","author":"H Xia","year":"2022","unstructured":"Xia H, Li S, Zhai X, Liu M, Guo X, Wang J (2022) The value of lymph node dissection in patients with node-positive upper urinary tract urothelial cancer: a retrospective cohort study. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.889144","journal-title":"Front Oncol"},{"key":"5605_CR28","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ et al (2019) Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 10:2977. https:\/\/doi.org\/10.1038\/s41467-019-10873-y","journal-title":"Nat Commun"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05605-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:53:55Z","timestamp":1767966835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05605-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5605"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05605-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board approval was obtained for the study (HS- 17 -\u200900168). A data-sharing agreement was secured at all participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"234"}}